Altschul David J, Esenwa Charles, Haranhalli Neil, Unda Santiago R, de La Garza Ramos Rafael, Dardick Joseph, Fernandez-Torres Jenelys, Toma Aureliana, Labovitz Daniel, Cheng Natalie, Lee Seon-Kyu, Brook Allan, Zampolin Richard
Department of Neurosurgery Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Department of Neurology Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Interv Neuroradiol. 2020 Oct;26(5):623-628. doi: 10.1177/1591019920954603. Epub 2020 Aug 30.
This study evaluates the mortality risk of patients with emergent large vessel occlusion (ELVO) and COVID-19 during the pandemic.
We performed a retrospective cohort study of two cohorts of consecutive patients with ELVO admitted to a quaternary hospital from March 1 to April 17, 2020. We abstracted data from electronic health records on baseline, biomarker profiles, key time points, quality measures and radiographic data.
Of 179 patients admitted with ischemic stroke, 36 had ELVO. Patients with COVID-19 and ELVO had a higher risk of mortality during the pandemic versus patients without COVID-19 (OR 16.63, p = 0.004). An age-based sub-analysis showed in-hospital mortality in 60% of COVID-19 positive patients between 61-70 years-old, 66.7% in between 51-60 years-old, 50% in between 41-50 years-old and 33.3% in between 31-40 years old. Patients that presented with pulmonary symptoms at time of stroke presentation had 71.4% mortality rate. 27.3% of COVID-19 patients presenting with ELVO had a good outcome at discharge (mRS 0-2). Patients with a history of cigarette smoking (p = 0.003), elevated d-dimer (p = 0.007), failure to recanalize (p = 0.007), and elevated ferritin levels (p = 0.006) had an increased risk of mortality.
Patients with COVID-19 and ELVO had a significantly higher risk for mortality compared to COVID-19 negative patients with ELVO. A small percentage of COVID-19 ELVO patients had good outcomes. Age greater than 60 and pulmonary symptoms at presentation have higher risk for mortality. Other risk factors for mortality were a history of cigarette smoking, elevated, failure to recanalize, elevated d-dimer and ferritin levels.
本研究评估了大流行期间急性大血管闭塞(ELVO)合并新型冠状病毒肺炎(COVID-19)患者的死亡风险。
我们对2020年3月1日至4月17日入住一家四级医院的两组连续ELVO患者进行了一项回顾性队列研究。我们从电子健康记录中提取了关于基线、生物标志物谱、关键时间点、质量指标和影像学数据的数据。
在179例因缺血性卒中入院的患者中,36例患有ELVO。与未感染COVID-19的患者相比,感染COVID-19且患有ELVO的患者在大流行期间的死亡风险更高(比值比16.63,p = 0.004)。基于年龄的亚组分析显示,61至70岁的COVID-19阳性患者中有60%在住院期间死亡,51至60岁的患者中有66.7%,41至50岁的患者中有50%,31至40岁的患者中有33.3%。卒中发作时出现肺部症状的患者死亡率为71.4%。27.3%出现ELVO的COVID-19患者出院时预后良好(改良Rankin量表评分0至2分)。有吸烟史(p = 0.003)、D-二聚体升高(p = 0.007)、未实现再通(p = 0.007)和铁蛋白水平升高(p = 0.006)的患者死亡风险增加。
与未感染COVID-19的ELVO患者相比,感染COVID-19且患有ELVO的患者死亡风险显著更高。一小部分感染COVID-19的ELVO患者预后良好。年龄大于60岁且发作时出现肺部症状的患者死亡风险更高。其他死亡风险因素包括吸烟史、D-二聚体和铁蛋白水平升高、未实现再通。